Dark Horse Consulting signed an MOU with Beijing-based CRO KunTuo Research and Development to help sponsors run cell and gene therapy trials in China while enabling reuse of data for future regulatory submissions elsewhere. The companies framed the partnership as a way to combine KunTuo’s trial services expertise with Dark Horse’s global regulatory strategy support. The deal targets global developers that want to accelerate recruitment and execution in China without losing flexibility for approvals outside the country. Dark Horse said KunTuo’s experience includes support across more than 1,000 drug trials, the majority involving advanced therapies. For sponsors, the data-reuse element is particularly relevant as cell and gene therapy developers weigh where to execute studies amid shifting regulatory expectations for international bridging and platform consistency.